Gender Disparities in Alcohol Use Disorder Treatment Among Privately Insured Patients with Alcohol-Associated Cirrhosis

被引:74
作者
Mellinger, Jessica L. [1 ]
Fernandez, Anne [2 ]
Shedden, Kerby [3 ]
Winder, G. Scott [2 ]
Fontana, Robert J. [1 ]
Volk, Michael L. [4 ]
Blow, Frederic C. [2 ,5 ]
Lok, Anna S. F. [1 ]
机构
[1] Univ Michigan, Div Gastroenterol & Hepatol, Ann Arbor, MI 48109 USA
[2] Univ Michigan, Dept Psychiat, Ann Arbor, MI 48109 USA
[3] Univ Michigan, Dept Stat, Ann Arbor, MI 48109 USA
[4] Loma Linda Univ Hlth, Inst Transplantat, Loma Linda, CA USA
[5] VA Ctr Clin Management Res, Ann Arbor, MI USA
关键词
Alcoholic Cirrhosis; Utilization; Substance Use Treatment; Female; NATIONAL EPIDEMIOLOGIC SURVEY; LIVER-DISEASE; RISK DRINKING; SUBSTANCE USE; DEPENDENCE; PREVALENCE; HEPATITIS; TRENDS; IDENTIFICATION; TOPIRAMATE;
D O I
10.1111/acer.13944
中图分类号
R194 [卫生标准、卫生检查、医药管理];
学科分类号
摘要
Background The burden of alcohol-associated cirrhosis (AC) is high, and though alcohol cessation improves mortality, many patients fail to engage in alcohol use disorder (AUD) treatment and continue drinking. Our aim was to determine rates, predictors, and outcomes of AUD treatment utilization in AC patients with private insurance. Methods We collected data from persons with AC (diagnosed by ICD-9/ICD-10 codes), aged 18 to 64 years, enrolled in the Truven MarketScan Commercial Claims and Encounters database (2009 to 2016). We determined rates and predictors of substance abuse treatment visits as well as rates of alcohol relapse prevention medication prescriptions, weighted to the national employer-sponsored insured population. Effects of AUD treatment utilization on decompensation rates were calculated using proportional hazards regression with propensity score adjustment. Results A total of 66,053 AC patients were identified, 32% were female, and mean age at diagnosis was 54.5 years. About 72% had insurance coverage for substance abuse treatment. Overall, AUD treatment utilization rates were low, with only 10% receiving a face-to-face mental health or substance abuse visit and only 0.8% receiving a Food and Drug Administration (FDA)-approved relapse prevention medication within 1 year of index diagnosis. Women were less likely to receive a face-to-face visit (hazard ratio [HR] 0.84, p < 0.001) or an FDA-approved relapse prevention medication (0.89, p = 0.05) than men. AC patients who had a clinic visit for AUD treatment or used FDA-approved relapse medication showed decreased risk of decompensation at 1 year (HR 0.85, p < 0.001 for either). Conclusions AUD treatment utilization is associated with lower decompensation rates among privately insured patients with AC. Women were less likely to utilize AUD treatment visits. Efforts to reduce gender-specific barriers to treatment are urgently needed to improve outcomes.
引用
收藏
页码:334 / 341
页数:8
相关论文
共 40 条
  • [21] FAILURE OF A 2-HOUR MOTIVATIONAL INTERVENTION TO ALTER RECURRENT DRINKING BEHAVIOR IN ALCOHOLICS WITH GASTROINTESTINAL-DISEASE
    KUCHIPUDI, V
    HOBEIN, K
    FLICKINGER, A
    IBER, FL
    [J]. JOURNAL OF STUDIES ON ALCOHOL, 1990, 51 (04): : 356 - 360
  • [22] Main Drivers of Outcome Differ Between Short Term and Long Term in Severe Alcoholic Hepatitis: A Prospective Study
    Louvet, Alexandre
    Labreuche, Julien
    Artru, Florent
    Bouthors, Alexis
    Rolland, Benjamin
    Saffers, Pierre
    Lollivier, Julien
    Lemaitre, Elise
    Dharancy, Sebastien
    Lassailly, Guillaume
    Canva-Delcambre, Valerie
    Duhamel, Alain
    Mathurin, Philippe
    [J]. HEPATOLOGY, 2017, 66 (05) : 1464 - 1473
  • [23] Alcohol consumption by cirrhotic subjects: Patterns of use and effects on liver function
    Lucey, Michael R.
    Connor, Jason T.
    Boyer, Thomas D.
    Henderson, J. Michael
    Rikkers, Layton F.
    [J]. AMERICAN JOURNAL OF GASTROENTEROLOGY, 2008, 103 (07) : 1698 - 1706
  • [24] Gabapentin Treatment for Alcohol Dependence A Randomized Clinical Trial
    Mason, Barbara J.
    Quello, Susan
    Goodell, Vivian
    Shadan, Farhad
    Kyle, Mark
    Begovic, Adnan
    [J]. JAMA INTERNAL MEDICINE, 2014, 174 (01) : 70 - 77
  • [25] Misconceptions, preferences and barriers to alcohol use disorder treatment in alcohol-related cirrhosis
    Mellinger, Jessica L.
    Winder, G. Scott
    DeJonckheere, Melissa
    Fontana, Robert J.
    Volk, Michael L.
    Lok, Anna S. F.
    Blow, Frederic C.
    [J]. JOURNAL OF SUBSTANCE ABUSE TREATMENT, 2018, 91 : 20 - 27
  • [26] The high burden of alcoholic cirrhosis in privately insured persons in the United States
    Mellinger, Jessica L.
    Shedden, Kerby
    Winder, Gerald Scott
    Tapper, Elliot
    Adams, Megan
    Fontana, Robert J.
    Volk, Michael L.
    Blow, Frederic C.
    Lok, Anna S. F.
    [J]. HEPATOLOGY, 2018, 68 (03) : 872 - 882
  • [27] Use of Administrative Claims Data for Identifying Patients with Cirrhosis
    Nehra, Mahendra S.
    Ma, Ying
    Clark, Christopher
    Amarasingham, Ruben
    Rockey, Don C.
    Singal, Amit G.
    [J]. JOURNAL OF CLINICAL GASTROENTEROLOGY, 2013, 47 (05) : E50 - E54
  • [28] Lifetime drinking history in patients with alcoholic liver disease and patients with alcohol use disorder without liver disease
    Nielsen, Jon Kristinn
    Olafsson, Sigurdur
    Bergmann, Ottar M.
    Runarsdottir, Valgerdur
    Hansdottir, Ingunn
    Sigurdardottir, Ragna
    Bjornsson, Einar S.
    [J]. SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (6-7) : 762 - 767
  • [29] Alcoholic Liver Disease
    O'Shea, Robert S.
    Dasarathy, Srinivasan
    McCullough, Arthur J.
    [J]. HEPATOLOGY, 2010, 51 (01) : 307 - 328
  • [30] Sex and age differences in the early identification and treatment of alcohol use: a population-based study of patients with alcoholic cirrhosis
    Otete, Harmony E.
    Orton, Elizabeth
    West, Joe
    Fleming, Kate M.
    [J]. ADDICTION, 2015, 110 (12) : 1932 - 1940